IASO Bio alongside Innovent unveiled fresh Equecabtagene Autoleucel (FUCASO®) findings for those affected by multiple myeloma, during the 2023 ASH conference.

Qilu Pharma Releases Initial Clinical Data on New Dual-Target Antibody QLS31905 During ESMO Immuno-Oncology Meeting.

Electra Therapeutics unveils initial study results from their active Phase 1b trial of ELA026 designed to combat secondary HLH (hemophagocytic lymphohistiocytosis)

Agenus Inc., an innovator in immune-modulatory cancer treatments, announced reaching its second milestone in the global licensing agreement with Bristol Myers Squibb for BMS-986442, a bispecific TIGIT antibody with improved Fc functionality.

Atara Biotherapeutics Unveils Encouraging Early Research Results for ATA3431, an Innovative Off-the-Shelf CAR Therapy Aimed at CD20 and CD19, at the 65th Annual Session of ASH.

The FDA has approved Pfizer’s review request for marstacimab, a hemophilia A/B treatment for non-inhibitor patients.

SystImmune and industry giant Bristol Myers Squibb have announced a partnership and licensing agreement focused on BL-B01D1, SystImmune's cutting-edge EGFRxHER3 bispecific antibody-drug conjugate.

Oculis Reveals Initial Participant Commencement in Phase 2b RELIEF Study for Topical Anti-TNFα Agent Licaminlimab (OCS-02) Aimed at Treating Dry Eye Conditions.

Xilio Therapeutics Announces Initiation of Enrollment for Phase 1 Combination Trial of XTX101, a Tumor-Activated, Fc-Enhanced Anti-CTLA-4, and Updated Phase 1 Monotherapy Data.

AltruBio Inc. starts Phase 2a trial for its drug ALTB-268 in ulcerative colitis patients with the first participant enrolled.

Vittoria Biotherapeutics Reveals US FDA Approval of Investigational New Drug Submission for VIPER-101 to Address T-Cell Lymphoma Therapy.

Bio-Thera Solutions, Ltd has made public the approval of their product Avzivi® (bevacizumab-tnjn) by the United States Food and Drug Administration.